BUILD THE RIGHT STRATEGY.
SECURE ACCESS.
DRIVE MARKET PERFORMANCE.

Jenette Bellitto is a Principal at BGBx Consulting, based in Washington, D.C. She joined BGBx from Kx Advisors and partners with clients ranging from emerging biotechs to global pharmaceutical leaders to unlock growth opportunities and guide high-impact portfolio and launch strategies. Jenette has deep expertise in voice-of-customer research, opportunity assessment, segmentation, market sizing, and new product strategy. She is known for bringing a rigorous, data-driven approach to navigating complex market dynamics and supporting confident decision-making across therapeutic areas including neuroscience, psychiatry, immunology, and medical aesthetics. Jenette holds a PhD in Biomedical Engineering from Yale University and a BS in Chemical Engineering from the University of California, Irvine.

Katie Devane is a Director at BGBx Consulting, based in Washington, D.C., where she partners with clients to solve complex challenges across the healthcare and life sciences landscape. She brings a strong foundation in applying data to inform strategy and decision-making. Katie is known for her analytical approach and her ability to translate complex insights into clear, actionable direction. She also plays a key role in mentoring and developing teams, fostering collaboration, and challenging thinking to drive stronger outcomes. Katie holds an MS from Northwestern University in Predictive Sciences and a BA from College of the Holy Cross.

Jennifer Dong is a Principal at BGBx Consulting, based in San Francisco, bringing a unique perspective shaped by her background in direct patient engagement and a deep understanding of the systemic and local challenges patients face in accessing quality healthcare. Her expertise lies in her ability to partner with clients to navigate complex access challenges that consider payer, provider, pharmacy, and patient behavior. Jenn is known for her collaborative approach, working closely with clients and teams to challenge assumptions, think differently, and translate insight into meaningful, patient-centered strategies. She enjoys tackling complex challenges with thoughtful teams and believes mutual accountability helps build true partnerships with clients. Jenn holds a MS in Biotechnology and Bioinformatics from UMGC as well as a BS in Bioengineering from the University of California, Berkeley.

Parrus Doshi is SVP, Global Brand Strategy at BGBx Consulting. He brings expertise across brand strategy, communications planning, and innovation, helping organizations translate complex market and behavioral insights into clear, actionable strategy. Parrus has partnered with global healthcare and consumer brands across a wide range of therapeutic and commercial categories, with a focus on shaping differentiated positioning, integrated communications, and behavior-changing campaigns. Prior to joining BGBx Consulting, Parrus held senior strategy leadership roles at McCann Health, where he led strategic planning initiatives across global healthcare brands and managed integrated strategy teams across EMEA. Earlier in his career, he also held strategy roles at TBWA\WorldHealth, Aesop Agency, and Brand and Deliver. Parrus holds a Bachelor’s Degree in Biomedical Science from King's College London.

Kimberly Dsilva is a Principal at BGBx Consulting, based in New York City, with a background spanning product strategy, customer experience, AI, and technology innovation across healthcare and enterprise organizations. She has led the design and deployment of scalable digital products and AI-enabled experiences for startups through Fortune 50 companies, translating complex data, user behavior, and market insights into customer-centered solutions used by millions.
Prior to joining BGBx Consulting, Kimberly held consulting and product strategy roles at Slalom and Accenture, where she led the CX strategy team in NYC and multiple digital transformation initiatives across cross-functional teams and emerging technology ecosystems. She is known for bridging strategy and execution—helping organizations operationalize innovation through human-centered design, data-driven decision-making, and cutting-edge technologies.
Kimberly holds a BS in Computer and Information Technology from Purdue University and a Master’s degree in User Experience Design from the Maryland Institute College of Art.

Masha Dumanis is a Senior Vice President at BGBx Consulting, based in Boston. She joined Kx Advisors (now BGBx Consulting) in 2024 to co-lead the MedTech practice. Masha is a recognized advisor in the MedTech and Digital Health sectors, with particular expertise in musculoskeletal (MSK), urology/pelvic health, and women's health markets. Masha brings 15 years of experience in healthcare strategy consulting, where she has supported clients across growth strategy, go-to-market planning, commercial due diligence, market access, M&A, and corporate strategy. She is known for building strong client partnerships and guiding data-driven decision-making in complex and evolving markets. Masha previously held leadership roles at Health Advances, where she led the MSK practice area. She holds an A.B. cum laude in Human Evolutionary Biology from Harvard College and serves as a Senior Advisor to the Journal of Orthopaedic Experience & Innovation (JOEI).

Allie is a Vice President at BGBx Consulting, based in Washington, D.C. Allie partners with clients to develop both upstream and downstream growth strategies across all of BGBx’s key sectors and therapeutic areas. Specifically, she collaborates with biopharmaceutical, medical device, and diagnostic companies, in therapeutic areas including cardiology and vascular health, medical aesthetics, and immunology. Functionally, Allie’s expertise encompasses market entry strategy, commercial due diligence, opportunity forecasting, and salesforce planning and optimization. Her work integrates data analytics, competitive intelligence, and voice-of-customer research to create simple and meaningful solutions to complex problems. Prior to BGBx, Allie worked with companies in the financial services and consumer goods industries as a strategy consultant. Allie holds a B.S. with Honors in Economics, with a Mathematical Economics concentration from Haverford College.

Anna Gaudio is SVP, CX Innovation at BGBx Consulting. She brings experience advising across customer experience, digital strategy, commercial strategy, and innovation, helping healthcare and life sciences organizations create more meaningful, engaging brand experiences that shape better health outcomes. Anna is known for practical integration of design thinking, behavioral insights, and emerging technologies to shape customer engagement strategies that drive growth, differentiation, and long-term brand value. Prior to joining BGBx Consulting, Anna held senior strategy and innovation leadership roles at McCann Health, Sera Prognostics, and ghg, greyhealth group, where she led customer experience, omnichannel engagement, and innovation initiatives across healthcare brands and therapeutic areas. She also serves as an Adjunct Professor at Utah Valley University, teaching experience mapping and communications planning at the MBA level. Anna holds a Master of Science in Marketing from Liberty University and a BS in Communication Studies from Liberty University.

Hilary Gentile is Chief of Commercial Strategy and Innovation at BGBx, where she leads the organization’s strategy and innovation efforts, overseeing the roadmap for BGBx’s AI-enabled technology suite and helping clients navigate increasingly complex commercial challenges. She focuses on integrating data, behavioral science, and emerging technologies to drive measurable business impact and more adaptive decision-making across the healthcare landscape.

With more than two decades of experience across healthcare and life sciences, Hilary brings deep expertise in commercial strategy, portfolio planning, organizational transformation, and innovation. She has led high-stakes launches, guided portfolio strategy, and supported transformation initiatives tied to mergers, acquisitions, and evolving commercial models. Hilary is recognized for helping organizations move beyond static planning toward more insight-driven, adaptive approaches to commercialization and has been featured at industry forums including the PM360 SPARK Transformation Summit. Hilary holds a bachelor's degree from Smith College, and an executive MBA from the NYU School of Business.

David Geschwind is a Vice President at BGBx Consulting, based in San Francisco. He brings extensive experience leading growth strategy engagements for pharmaceutical, biotechnology, MedTech, and digital health companies, with a focus on product launch strategy, commercial operations, financial modeling and forecasting, commercial due diligence, pricing, and market access. David's previous experience includes roles at Kx Advisors, where he advised clients across therapeutic areas including interventional medicine, medical aesthetics, eye care, dermatology, and oncology. He is known for translating complex market and financial dynamics into clear, actionable strategy. David holds a B.A. in Computer Science and Economics from Swarthmore College.

Marc Geschwind is a Principal at BGBx Consulting, based in New York City. He joined Kx Advisors (now BGBx Consulting) in 2019. Marc brings broad experience leading growth strategy engagements across medical aesthetics, pharmaceutical, MedTech, and animal health sectors, advising clients on brand and franchise planning, commercial operations, product and portfolio strategy, and competitive response planning. In previous roles, Marc developed particular expertise in medical aesthetics, supporting engagements across injectables, skincare, and energy-based devices. His broader therapeutic experience spans cardiovascular disease, neurology, orthopedics, inflammatory diseases, and plastic and regenerative medicine. Marc holds a BA in Economics from Swarthmore College.

Steve Goldstein is EVP, Marketing and Product Development at BGBx Consulting. His experience spans more than 25 years across pharmaceutical commercialization, brand strategy, and product launch planning, helping healthcare organizations navigate complex commercial and market access challenges across multiple therapeutic areas. Steve has deep expertise across immunology, oncology, neurology, and gastroenterology, with experience leading HCP and DTC strategy for major brand launches and lifecycle planning initiatives across global and US markets. Prior to joining BGBx Consulting, Steve held senior commercial leadership roles at Bristol Myers Squibb and Novartis, where he led launch, lifecycle management, and consumer marketing initiatives across numerous portfolios. Steve holds a BSBA in Finance and International Business from Washington University in St. Louis.

Katie Harris is a Principal at BGBx Consulting, based in San Francisco, where she partners closely with clients to deliver strategic, creative solutions that drive meaningful results across the life sciences landscape. She brings a collaborative, client-focused approach to solving complex challenges and advancing growth strategies. Katie is known for leading high-performing teams, fostering strong partnerships, and bringing clarity and energy to every engagement while helping develop the next generation of talent. Katie was formerly a senior leader at Hayden Consulting Group, a corporate strategist, and a consultant at IQVIA. Katie holds a BA in International Relations from Brown University.

Tess Huffstater is a Principal at BGBx Consulting, based in Boston. She joined BGBx from Kx Advisors and brings deep expertise in asset and portfolio strategy across oncology, immunology, and rare diseases. Tess partners with biopharma and biotech clients to define strategic direction at critical decision points, from early clinical development through commercial readiness. She is known for bridging scientific and commercial thinking, building cross-functional alignment, and bringing clarity and structure to complex decisions in drug development. Tess holds a B.S. and M.Eng. in Biomedical Engineering from Cornell University and a PhD in Biomedical Engineering from Vanderbilt University, where her research focused on novel drug targets for kidney disease.

Sonya Jakawich is a Senior Vice President at BGBx Consulting, based in New York City. She joined BGBx from Kx Advisors and brings more than 13 years of experience in life sciences strategic advisory, partnering with organizations across the healthcare ecosystem to shape early product and portfolio strategies. Sonya has advised global pharmaceutical companies, emerging biotechs, and investment firms on strategic decision-making across therapeutic areas including oncology, obesity/T2D, and immunology. She has also held roles at Pfizer and Trinity Life Sciences, developing a strong foundation in both scientific and commercial strategy. She holds a PhD in Neuroscience from the University of Michigan and a BS in Cellular and Molecular Biology from the University of Washington.

Jenny Knauss is a Vice President at BGBx Consulting with nearly a decade of experience across healthcare consulting and communications. She brings deep expertise in oncology, spanning both solid tumors and hematologic malignancies, and applies principles of strategy and development in complex disease states across therapeutic areas. Jenny leads the Medical and Evidence Strategy practice area at BGBx, where she partners with Medical Affairs and Commercial teams to inform strategy from early clinical development, landscape analysis, and evidence generation through launch planning, brand strategy, and lifecycle management. Jenny joined BGBx from Kx Advisors and previously held roles at BGB Group and McKinsey & Company, giving her a unique perspective across strategy and execution. She holds a PhD in Cell and Developmental Biology from Weill Cornell Medicine Graduate School of Medical Sciences and a BS in Biology from American University.

Kalynn Kresge is EVP at BGBx Consulting, based in the New York City metropolitan area. She brings specialized expertise at the intersection of strategy, innovation, data, and technology—helping healthcare and life sciences organizations translate complex market, customer, and performance data into actionable commercial growth strategies. Kalynn is known for connecting insight, advanced analytics, and behavioral understanding to shape differentiated go to market strategu, accelerate decision-making, and drive measurable business impact. Prior to joining BGBx Consulting, Kalynn held senior leadership roles at Innovation x Intelligence, 90North, an IPG Health Company, and McCann Health, where she led strategic planning and innovation initiatives across a broad range of healthcare brands and therapeutic areas. She holds a BA in Biology, with minors in Business and Psychology, from Lehigh University.

Nikil Kumar is a Partner at BGBx Consulting, based in New York. He joined BGBx from Kx Advisors and brings experience partnering with pharmaceutical and biotech organizations to develop pragmatic, growth-focused strategies, with particular depth in oncology across both solid and hematologic malignancies. Nikil has led engagements spanning market opportunity assessment, portfolio strategy, product launch planning, and marketing strategy. He has also held strategy consulting roles at Omnicom Health Group, giving him a strong foundation in translating strategy into effective market execution. He holds a BS in Neuroscience from Stony Brook University.

Philipp is a Principal at BGBx Consulting based in London. He partners with clients ranging from emerging biotech companies to global pharmaceutical organizations on portfolio and launch strategy across therapeutic areas including immunology, oncology, and rare diseases. Philipp has deep expertise spanning opportunity assessments, competitive wargaming, brand planning, and lifecycle management for pipeline and established assets, helping inform commercialization and investment decisions. He is known for bringing a rigorous and analytically driven approach to complex business challenges, helping clients navigate evolving market dynamics and make confident strategic decisions. Philipp earned an MSci (Hons) in Chemistry and a PhD in Inorganic Chemistry from the University of Nottingham, UK.

Sean Vander Linde is a Partner at BGBx Consulting, based in Washington, D.C. He joined BGBx from Kx Advisors and brings deep experience advising organizations across the healthcare value chain, including providers, health IT, biopharma, and medical device companies. With extensive experience leading engagements focused on corporate strategy, market opportunity assessment, product launch planning, and commercial due diligence, Sean's work is centered on helping clients navigate complex market dynamics and translate strategic insight into actionable growth plans. Sean previously held roles at Kaiser Associates, L.E.K. Consulting, and PwC, where he focused on healthcare strategy and transformation. Sean holds an MBA from the Tuck School of Business at Dartmouth and a BA in Political Science from the University of North Carolina at Chapel Hill.

Chloe Lok is a Vice President at BGBx Consulting, based in London. She brings over 10 years of experience in the healthcare industry, leading engagements across pharmaceutical, biotechnology, and digital health organizations. She joined BGBx from Kx Advisors and brings deep expertise in rare diseases, immunology, and hematology, with additional experience spanning respiratory and psychiatry. Chloe partners with global clients to shape asset and portfolio strategy, guide launch planning, and navigate complex commercial and clinical landscapes. She is known for her ability to integrate qualitative and quantitative insights into clear, actionable strategy, with strengths in strategic marketing, patient journey mapping, and forecasting. Chloe holds an MSc in Management from Imperial College Business School and a BSc in Biochemistry from the University of Reading.

Dave MacDougall is a Managing Director at BGBx Consulting, based in Boston. He joined BGBx from Hayden Consulting Group, which he co-founded, and brings a deep background in business and market access to solve complex client needs and unlock growth opportunities. Dave is known for helping clients integrate market access into overall commercialization strategy, with a focus on the intersection of data-driven decision-making and strategic insight. In addition to working closely with clients, he plays a key role in evolving capabilities, processes, and culture to support continued growth. Dave holds an MBA from Babson College and a BS in Biochemistry from Suffolk University.

Hugh MacKinnon is a Vice President at BGBx Consulting, based in the United Kingdom. He brings significant experience leading AI strategy, digital transformation, and innovation initiatives across healthcare and regulated industries. Hugh specializes in helping organizations translate emerging technologies into practical, scalable solutions that improve decision-making, customer experience, and commercial performance. Prior to joining BGBx Consulting, Hugh led innovation and creative strategy initiatives at Havas SO and advised organizations on AI transformation as an independent consultant. He has experience designing and implementing AI pilots, innovation programs, and customer experience strategies across global healthcare organizations and emerging markets. Hugh holds a BS in Biological Sciences from The University of Edinburgh and completed Continuing Studies coursework in innovation and problem solving at Stanford University.

Bryan McDonald is a Principal at BGBx Consulting, based in New York City, where he partners with pharmaceutical and life sciences organizations to develop data-driven commercial and market access strategies. He brings more than a decade of experience leveraging real-world data, primary research, and structured analytical frameworks to break down complex market challenges and inform commercialization, forecasting, and market access decision-making. Bryan is known for his collaborative approach and commitment to mentoring and developing teams. Prior to joining BGBx Consulting, Bryan worked within IQVIA’s Market Access Strategy Consulting Group. He holds a BS in Biology & Society from Cornell University.

Sam McMeley is a Principal at BGBx Consulting, where he focuses on solving life sciences challenges that sit at the intersection of market access and commercial strategy. He works primarily in oncology and other clinically and logistically complex therapeutic areas where finding the right answer requires deep understanding of the interlocking and evolving components of the US healthcare system. His strength lies in breaking down complex issues into clear, actionable insights that executives and cross-functional teams act upon. Sam has gained deep experience through progressively increasing role of responsibility at Hayden Consulting Group, Charles River Assciates, in private equity at Touchdown Ventures. Sam holds a BA in Molecular, Cellular and Developmental Biology from the University of Colorado at Boulder.

Hailey is a Principal at BGBx Consulting and is based in Washington, DC. She joined BGBx from Kx Advisors and partners with MedTech, Digital Health, and Health IT clients to identify and unlock growth opportunities.

Hailey has extensive experience leading strategy engagements, with a particular emphasis on commercial due diligence, M&A, and commercial growth. With deep expertise in Voice of Customer market research and survey, she is known for uncovering and synthesizing insights into actionable narratives that bring clarity to clients’ biggest strategic questions.

Hailey holds an MPhil in International Relations and Politics from the University of Cambridge and a BA in International Affairs from The George Washington University.

Tanya Myler is an Associate Principal at BGBx Consulting, based in Pittsburgh, Pennsylvania. She joined BGBx from Hayden Consulting Group and brings deep experience advising life sciences organizations across oncology and CNS therapeutic areas. Tanya specializes in commercial launch readiness, market access strategy, and the integration of innovative digital technologies into healthcare systems. With a background that bridges science and strategy, Tanya has supported pharmaceutical and healthcare clients on growth strategy, commercialization planning, and strategic decision-making in complex and evolving markets. Earlier in her career, she held consulting roles at Accenture, Bionest Partners, Guidehouse, and Navigant Consulting. Tanya holds a PhD in Biochemistry from The University of Texas at Austin.

Dan O’Neill is a Managing Partner at BGBx Consulting. He is based in Washington, D.C. With nearly two decades of experience advising leading life sciences organizations, Dan has deep expertise developing commercial growth strategies for pharmaceutical and medical device executives. Prior to BGBx, Dan co-founded Kx Advisors, and earlier in his career advised clients as the head of the Healthcare Practice at Kaiser Associates. With a focus on new product planning, portfolio strategy, commercial due diligence, go-to-market strategy, and competitive planning, Dan has expertise in integrated research and quantitative modeling techniques related to product pricing and forecasting. Dan started his career in finance and banking, where he developed his quantitative background. Dan holds an MBA from the McDonough School of Business at Georgetown University and a BBA from the University of Kentucky.

Tavishi Pandey is a Senior Manager at BGBx Consulting. She joined BGBx from Hayden Consulting Group and brings experience advising life sciences organizations on commercial strategy, analytics, and market access–related initiatives. Tavishi has supported clients across a range of strategic engagements, with a focus on translating complex market and business data into actionable insights that inform commercial decision-making. Prior to Hayden Consulting, Tavishi held consulting roles at IQVIA, where she developed experience in healthcare analytics and life sciences strategy. She holds a Master of Science in Business Analytics from the Questrom School of Business, Boston University and a BA in Psychology and Entrepreneurial and Leadership Studies from Tufts University.

Andy Pollpeter is a Director at BGBx Consulting, where he partners with clients to navigate the evolving landscape of U.S. market access and reimbursement. He brings deep experience leveraging real-world data to inform commercial decision-making and access strategy. Andy is known as a highly engaged project leader, coach, and mentor who challenges teams to think creatively and strategically while delivering clear, actionable insights.

Bob Serrano is a Managing Partner at BGBx Consulting, based in Washington, D.C. He brings over two decades of experience across the healthcare industry, with a focus on developing growth strategies for specialty pharmaceutical, biotech, and medical device companies. Bob has advised leading life sciences companies on strategic growth, market development, and commercial execution. His work spans a wide range of therapeutic areas, including oncology, neurology, immunology, and infectious diseases, with a consistent focus on translating complex market dynamics into clear, actionable strategy. Bob co-founded Kx Advisors, and co-led the Healthcare Practice at Kaiser Associates. Earlier in his career Bob held commercial roles Abbott Laboratories (now AbbVie), where he gained firsthand experience in commercial strategy. He also led North American laboratory marketing for QIAGEN’s molecular diagnostics business, bringing a deep understanding of how strategy translates into execution in highly technical and regulated markets. Bob earned an MBA from the Kellogg School of Management at Northwestern University, as well as a Master’s in Health Administration and a BS in Nutritional Science from Cornell University.

Jamie Sidore is a Managing Director at BGBx Consulting, based in Boston, bringing deep expertise at the intersection of commercial strategy and market access. He joined BGBx from Hayden Consulting Group, which he co-founded to help life sciences organizations integrate access considerations into broader commercialization strategy. Jamie is known for building high-impact client partnerships, developing new capabilities, and shaping teams that can navigate complex market dynamics with clarity and confidence. He has worked in strategy consulting for over 25 years, including previous leadership roles at Parexel, IQVIA and Amundsen Group. Jamie holds an MBA from Yale University School of Management, and a BA from Duke University.

Max Tabb is a Senior Principal at BGBx Consulting, based in Boston, where he helps clients understand how market access dynamics shape brand, portfolio, and corporate strategy. He is a core contributor to thought leadership and plays a key role in advancing learning and development programs. Max brings a strategic, access-informed lens to complex decisions, helping teams connect market dynamics to actionable commercial strategy. Prior to Hayden, Max worked with large, integrated health systems at Chartis Group, at IQVIA, and started his career at the Amundsen Group. Max holds an MBA from the University of Chicago Booth School of Business, and a BA in Economics from Tufts University.

Andy Therrien is an Associate Principal at BGBx Consulting. He joined BGBx from Hayden Consulting Group and brings a strong background in advising pharmaceutical and medical device organizations on commercialization strategy, product launch planning, market access, and pricing strategy. Andy has deep expertise helping clients navigate complex market dynamics and translate strategic insight into actionable commercial plans. Andy has led cross-functional engagements focused on commercialization, market research, pricing, and access strategy across the life sciences industry. Earlier in his career, he held consulting roles at EVERSANA and EQUITAS Life Sciences. Earlier in his career, Andy conducted advanced scientific research as a Postdoctoral Scholar at University of California, Santa Barbara. He holds a PhD in Chemistry from Tufts University and a BS in Chemistry from Saint Michael's College.

Mudita Vaish is a Partner at BGBx Consulting, based in London. She joined Kx Advisors (now BGBx Consulting) in 2025 and leads the London office. She brings more than 15 years of consulting experience focussed in the healthcare and life sciences industry, with deep expertise in commercial launch strategy, data-driven brand planning, and AI-enabled insights. Mudita has advised leading global pharmaceutical companies on market entry, brand planning, launch execution and asset performance tracking, across therapeutic areas including oncology, immunology, ophthalmology, neurology, and rare diseases. She has also held life sciences and healthcare commercial strategy roles at IQVIA and PwC Strategy&, helping clients shape data-driven strategies across EMEA. Mudita holds an MSc in Management and Strategy from the London School of Economics and Political Science, an MSc in Economics from Indira Gandhi Institute of Development Research, and a BA in Economics from the University of Delhi.

Chris Waybill is a Partner and AI Solutions Leader based in the San Francisco Bay Area, advising life sciences companies on high-stakes strategic decisions across the asset lifecycle. With over a decade in strategy consulting at Kx Advisors (now BGBx Consulting), he has led more than 200 engagements spanning corporate strategy, new product planning, and commercial strategy and launch planning. His work centers on moments that define asset success, most notably the transitions from Phase 2 to Phase 3 and from Phase 3 to launch, where clinical, commercial, and investment decisions converge. Chris helps clients translate early signals into actionable strategy, shaping evidence generation, competitive positioning, and go-to-market pathways to maximize probability of success and long-term value. Chris brings broad therapeutic area experience, with a primary focus in CNS, dermatology, immunology, and medical aesthetics, and additional depth across medtech and diagnostics, including interventional devices, connected wearables, and advanced diagnostic platforms. As AI Solutions Leader, Chris is redefining how strategy is built and delivered at Kx. He leads efforts to embed AI and technology-enabled capabilities into core workflows, driving faster insight generation, more dynamic decision-making, and scalable, repeatable approaches to complex strategic problems. He holds a B.S.E. in Mechanical Engineering & Materials Science from Duke University.